- Home
- MQ vs ZLAB Comparison
MQ vs ZLAB Comparison
Compare MQ & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MQ | ZLAB |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MQ | ZLAB |
|---|---|---|
| Price | $4.80 | $19.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $5.36 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 3.7M | 832.3K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $588,561,000.00 | $441,629,000.00 |
| Revenue This Year | $25.93 | $26.16 |
| Revenue Next Year | $18.46 | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.11 | ★ 24.14 |
| 52 Week Low | $3.48 | $16.82 |
| 52 Week High | $7.04 | $44.34 |
Technical Indicators
Market Signals| Indicator | MQ | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 51.76 |
| Support Level | $4.59 | $17.18 |
| Resistance Level | $4.98 | $17.97 |
| Average True Range (ATR) | 0.13 | 0.61 |
| MACD | -0.02 | 0.33 |
| Stochastic Oscillator | 31.82 | 85.00 |
Price Performance
Historical ComparisonAbout MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.